Response: Intrathecal methotrexate and central nervous system events

Blood. 2009 Aug 27;114(9):1999-2000. doi: 10.1182/blood-2009-06-226076.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Central Nervous System Diseases / chemically induced*
  • Central Nervous System Diseases / prevention & control
  • Combined Modality Therapy
  • Cyclophosphamide / adverse effects
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / adverse effects
  • Doxorubicin / therapeutic use
  • Humans
  • Immunotherapy
  • Injections, Spinal / methods*
  • Lymphoma, Large-Cell, Anaplastic / drug therapy*
  • Lymphoma, Large-Cell, Anaplastic / immunology*
  • Lymphoma, Large-Cell, Anaplastic / pathology
  • Lymphoma, Large-Cell, Anaplastic / radiotherapy
  • Methotrexate / adverse effects*
  • Methotrexate / therapeutic use*
  • Prednisone / adverse effects
  • Prednisone / therapeutic use
  • Prognosis
  • Research Design
  • Risk
  • Treatment Outcome
  • Vincristine / adverse effects
  • Vincristine / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone
  • Methotrexate

Supplementary concepts

  • CHOP protocol